ASH2023: i lavori GIMEMA presentati al congresso dell’American Society of Hematology

Il 65° congresso della Società americana di ematologia (ASH – American Society of Hematology) si terrà dal 9 al 12 dicembre 2023 a San Diego, in California, sia in presenza sia in modalità online. Il GIMEMA sarà presente con suoi lavori e ricercatori.

L’evento annuale dell’ASH è composto da numerose sessioni, eventi e differenti attività. Il programma è consultabile sul sito dell’ASH, oltre che attraverso l’applicazione mobile dell’ASH.

Sono oltre 7 mila gli abstract accettati che rappresentano la ricerca scientifica più all’avanguardia in ematologia. Per permettere ai partecipanti di poterli visionare, la Società americana di ematologia ha organizzato i Poster Walks che si svolgeranno virtualmente e di persona. Le “passeggiate” saranno composte da circa sei poster presentati da una breve introduzione e accompagnati da un momento interattivo di domande e risposte tra gli organizzatori della sessione, gli autori degli abstract e il pubblico virtuale.

Ecco gli abstract GIMEMA che verranno presentati al congresso ASH2023:

Leucemia linfoblastica acuta

Orale:

• Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial
  Chiaretti S, et al.

Poster:

• LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acute Lymphoblastic Leukemia
  Foà R, et al.
• Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial
  Chiaretti S, et al.
• A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era
  Piciocchi A, et al.

Leucemia mieloide acuta

Poster:

• Final analysis for the primary end-point of GIMEMA AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of non Low-Risk Acute Myeloid Leukemia
  Marconi G, et al.
• Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial
  Minetto P, et al.
• Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML
  Minetto P, et al.
• Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype
  Bartalucci n, et al.
• Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial
  Venditti A, et al.

Leucemia mieloide cronica

Poster:

• International, prospective study comparing Nilotinib versus Imatinib with early switch to Nilotinib to obtain sustained treatment-free remission in patients with chronic myeloid leukemia (SUSTRENIM trial): analysis of the eligibility to treatment discontinuation
  Pane F, et al.

• On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)
  Abruzzese E, et al.

Leucemia linfatica cronica

Poster:

• 36-Month Follow-up Results of the Gimema Veritas Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile
  Mauro FR, et al.

Leucemia promielocitica acuta

Orale:

• Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study
  Guarnera L, et al.

Qualità di vita

Poster:

• Patients’ Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform
  Efficace F, et al.
• Lifestyle Behaviors and Health-Related Quality of Life in Long-Term Survivors of Acute Myeloid Leukemia: An International Survivorship Study By the Gimema, EORTC Quality of Life and Leukemia Groups
  Efficace F, et al.
• Association of Financial Toxicity and Health-Related Quality of Life in Long-Term Survivors of Acute Promyelocytic Leukemia Treated within a Universal Healthcare System
  Sparano F, et al.
• Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study
  Caocci G, et al.

Sono inoltre state selezionati solo come pubblicazioni i seguenti lavori:

• Snapshot of the Management of ChronicLymphocytic Leukemia in Italy. PreliminaryAnalysis on over 3000 Patients Enrolled inthe Gimema CLL2121 Trial
  Scarfò L, et al.
• Health-Related Quality of Life Profile and Symptom Burden of Patients with Aggressive B-Cell Lymphomas Just before CAR-T-Cell Therapy: A Real-World Study By the Gimema
  Efficace F, et al.
• Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes
  Fianchi L, et al.

Qui l’elenco dei lavori GIMEMA presentati all’ASH2022.